• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    NightHawk Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    1/11/24 4:59:34 PM ET
    $NHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NHWK alert in real time by email
    false 0001476963 0001476963 2024-01-08 2024-01-08 0001476963 us-gaap:CommonStockMember 2024-01-08 2024-01-08 0001476963 NHWK:CommonStockPurchaseRightsMember 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): January 8, 2024

     

    NightHawk Biosciences, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-35994 26-2844103
    (Commission File Number) (IRS Employer Identification No.)

     

    627 Davis Drive, Suite 300

    Morrisville, North Carolina 27560

    (Address of principal executive offices and zip code)

     

    (919) 240-7133

    (Registrant’s telephone number including area code)

     

    N/A

    (Former Name and Former Address)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.0002 par value per share NHWK NYSE American LLC
    Common Stock Purchase Rights None NYSE American LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨  

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     
     
     
     

     

     

    Item 8.01 Other Items

    On January 8, 2024, NightHawk Biosciences, Inc. ( the “Company”) issued a press release announcing that it is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO. The Company will continue to operate its CDMO within the Scorpius BioManufacturing, Inc. subsidiary. In connection with the name change, the Company’s ticker will change to SCPX. The Company has determined to effectuate the name change on January 22, 2024

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.  
           
      Exhibit
    Number
      Description
       99.1   Press Release dated January 8, 2024 (Incorporated by reference as Exhibit 99.1 to Form 8-K filed with the Securities and Exchange Commission on January 8, 2024)
      104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

     

     

     

     

     

     
     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated:  January 11, 2024

    NightHawk Biosciences, Inc.

       
         
      By: /s/ Jeff Wolf
      Name:

    Jeff Wolf

      Title: Chief Executive Officer

     

     

     

    Get the next $NHWK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NHWK

    DatePrice TargetRatingAnalyst
    More analyst ratings